ライフサイエンスコーパス: adjunctive therapy

1 n coagulation (IAC), is now commonly used as adjunctive therapy.

2 (VNS) is licensed in several countries as an adjunctive therapy.

3 stered antifungal agent, may be an effective adjunctive therapy.

4 medical therapy and thus might be useful as adjunctive therapy.

5 Transsphenoidal adenomectomy and as-needed adjunctive therapy.

6 often given as monotherapy as well as early adjunctive therapy.

7 , baclofen and other medications are used as adjunctive therapy.

8 part of the aim of all chemical anti-plaque adjunctive therapy.

9 ole for MIF as a target of immune-modulating adjunctive therapy.

10 nti-CPS mAbs encourages their development as adjunctive therapy.

11 on of VT is currently recommended only as an adjunctive therapy.

12 AgNPs are a reasonable alternative to MMC as adjunctive therapy.

13 temic compartments are needed for effective, adjunctive therapy.

14 med at using virulence factor antagonists as adjunctive therapies.

15 ), provides a range of molecular targets for adjunctive therapies.

16 ncluding ease of dosing and combination with adjunctive therapies.

17 ortant advances in intravenous nutrition and adjunctive therapies.

18 ysiology as well as the influence of age and adjunctive therapies.

19 rther enhancements in clinical outcomes, and adjunctive therapies.

20 mpairments in patients with schizophrenia as adjunctive therapies.

21 r severe or complicated CDI, with or without adjunctive therapies.

22 mportant implications for the development of adjunctive therapies.

23 have stimulated research efforts to develop adjunctive therapies.

24 tification of new clinical interventions and adjunctive therapies.

25 lity is high and so attention has focused on adjunctive therapies; adjunctive corticosteroids are ben

26 The correct adjunctive therapy administered along with reperfusion h

27 eding and suggest it is a safe and effective adjunctive therapy after variceal obliteration technique

28 Consequently, different adjunctive therapies aimed at modulating malaria pathoph

29 This intervention could prove useful as an adjunctive therapy aimed at reducing mortality rates in

30 myocardial infarct size by administration of adjunctive therapies along with reperfusion therapy.

31 Is laser therapy, as a monotherapy or as an adjunctive therapy, an efficacious treatment modality fo

32 l data are needed on selection and dosing of adjunctive therapies and on complications in the elderly

33 spontaneously cleared the infection without adjunctive therapy and demonstrated higher levels of Th2

34 Novel trial designs, such as time-to-event adjunctive therapy and historical-control monotherapy, m

35 us open surgical treatment, regenerative and adjunctive therapies, and other important aspects of CLI

36 ferences may reflect differing trial design, adjunctive therapies, and/or limited power.

37 event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches.

38 to develop toxin-neutralizing antibodies as adjunctive therapies are justified, given the high morta

39 ion, newer treatments that are used as early adjunctive therapy are dorzolamide, brinzolamide, apracl

40 and therefore represents a prime target for adjunctive therapy based on small-molecule kinase inhibi

41 ted a possible role for anti-TNF antibody as adjunctive therapy, but this possibility requires confir

42 specialized enteral formula can be a useful adjunctive therapy by reducing lung inflammation and imp

43 cking, pharmacologic and/or nonpharmacologic adjunctive therapy can be helpful in the treatment of th

44 al strategies may lead to the development of adjunctive therapies capable of improving outcomes.

45 pport routine nutritional supplementation or adjunctive therapies compared with standard care.

46 fforts focus on improving antiretroviral and adjunctive therapies, defining disease onset and progres

47 esults from SMC hyperplasia and suggest that adjunctive therapies designed to inhibit SMC proliferati

48 tion and suggests avenues for development of adjunctive therapy designed to augment host immunity.

49 Adjunctive therapy did not improve the likelihood of sur

50 -10-related mechanisms that could be used as adjunctive therapies during tuberculosis.

51 f such epileptogenesis remain unknown and no adjunctive therapy during cerebral malaria has been show

52 ycophenolic acid, exploration of alternative adjunctive therapies (eg, a mammalian target of rapamyci

53 When mechanical ventilation and adjunctive therapies fail, extracorporeal life support c

54 These findings might impact adjunctive therapies for cancer.

55 enzyme replacement for storage disorders and adjunctive therapies for metabolic disorders, as well as

56 tial attractive target for immune-modulating adjunctive therapies for neonatal sepsis.

57 eview present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the

58 These findings suggest that alternative or adjunctive therapies for stent thrombosis are needed.

59 emains a strong need for non-antiarrhythmic, adjunctive therapies for the prevention of postoperative

60 e effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment.

61 et agents may prove beneficial in developing adjunctive therapies for use in combination with combine

62 iation is one of the most prevalent forms of adjunctive therapy for a variety of cancers, these resul

63 in for AMI were randomly assigned to receive adjunctive therapy for at least 3 days with either enoxa

64 n, and calcineurin inhibitors may provide an adjunctive therapy for biliary pancreatitis.

65 Antidepressants may not be useful adjunctive therapy for bipolar depressed patients with h

66 initiated clinical trials by using rBPI21 as adjunctive therapy for children with severe meningococce

67 f riluzole, a glutamatergic modulator, as an adjunctive therapy for children with treatment-resistant

68 t DON as a strong candidate for an effective adjunctive therapy for CM in African children.

69 thogenesis and nimodipine holds potential as adjunctive therapy for CM.

70 MK2 inhibition may be a valuable adjunctive therapy for control of pemphigus blistering.

71 /UNICEF strategy for zinc supplementation as adjunctive therapy for diarrhea is poorly implemented.

72 reasoned that COP-1 could be developed as an adjunctive therapy for disease.

73 of studies is emerging that shows benefit of adjunctive therapy for DME.

74 ompared with unfractionated heparin (UFH) as adjunctive therapy for fibrinolysis in patients with ST-

75 rategy of using enoxaparin instead of UFH as adjunctive therapy for fibrinolysis in patients with STE

76 n when enoxaparin was used instead of UFH as adjunctive therapy for fibrinolysis in patients with STE

77 gG conjugates merit further study as a novel adjunctive therapy for gram-negative sepsis.

78 Nonstatin lipid-lowering therapy is adjunctive therapy for high-risk individuals on statins

79 ase and as such warrants further study as an adjunctive therapy for human disease.

80 hen neurostimulation may become available as adjunctive therapy for medically intractable epilepsy.

81 ential clinical utility as either primary or adjunctive therapy for nephrotic syndrome or other disea

82 Furthermore, HO inhibitors may be useful adjunctive therapy for NTS infection in the context of h

83 mprovement in function and pain relief as an adjunctive therapy for osteoarthritis of the knee when c

84 neuropathy, generalized anxiety disorder and adjunctive therapy for partial seizures of epilepsy.

85 e been reported that support the efficacy of adjunctive therapy for patients with bipolar I depressio

86 esults suggest that estrogen may be a useful adjunctive therapy for patients with CHF.

87 X-2 inhibitors have been approved for use as adjunctive therapy for patients with familial polyposis.

88 superior to unfractionated heparin (UFH) as adjunctive therapy for patients with ST-segment elevatio

89 This approach might be a useful adjunctive therapy for patients with uncontrolled hypert

90 use, has the potential to be developed as an adjunctive therapy for PcP.

91 cogene c-fosDLCs could represent a promising adjunctive therapy for restoring iodide avidity within t

92 Adjunctive therapy for severe malaria has been seen as a

93 he possible development of brexanolone as an adjunctive therapy for SRSE requiring pharmacological co

94 ic therapies are beginning to be explored as adjunctive therapy for steroid-refractory ulcerative col

95 in of Mycobacterium bovis, is widely used as adjunctive therapy for superficial bladder cancer.

96 attractive candidate for further study as an adjunctive therapy for the elimination of the latent HIV

97 te that inhibition of IKK may serve as novel adjunctive therapy for the prevention of graft rejection

98 ential importance of dietary phytosterols as adjunctive therapy for the treatment of hypercholesterol

99 aPDT is an effective adjunctive therapy for the treatment of periodontitis in

100 ermore, enhancing M2a polarization may be an adjunctive therapy for the treatment of Pneumocystis.

101 an indirect-acting antithrombin, heparin, as adjunctive therapy for thrombolysis in myocardial infarc

102 lin-1, and CD82 function may be an effective adjunctive therapy for treating epithelial cell malignan

103 ch indicate that rG-CSF may be beneficial as adjunctive therapy for treatment of serious bacterial an

104 mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset s

105 Although corticosteroids are recommended as adjunctive therapy for tuberculous meningitis, the mecha

106 se), 0.4 mug/kg/hr (low dose), or placebo as adjunctive therapy for up to 5 days or resolution of wit

107 igned to enhance satiety may be an effective adjunctive therapy for weight loss; however, more resear

108 uggest that adaptive WMT may be an effective adjunctive therapy for WM deficits in HIV participants.

109 sy, quite a few of these studies showed that adjunctive therapy further reduced myocardial infarct si

110 ts, improvement of endoscopic technique, and adjunctive therapy, further reduction in recurrence rate

111 Several adjunctive therapies have undergone clinical trials in t

112 ntion by treatment assignment and the use of adjunctive therapies in 18 randomized clinical trials en

113 n and corticosteroids are both commonly used adjunctive therapies in septic shock.

114 HDTs hold significant promise as adjunctive therapies in that they are less likely to eng

115 ventilator-induced lung injury and other new adjunctive therapies in the care of these patients.

116 n strategies as well as newer antithrombotic adjunctive therapies in the elderly with STEMI.

117 psychological interventions may be important adjunctive therapies in the medical management of RA.

118 Alendronate is a useful adjunctive therapy in combination with enzyme replacemen

119 treatment of other atopic diseases and as an adjunctive therapy in conjunction with allergen-specific

120 aparin may potentially substitute for UFH as adjunctive therapy in fibrin-specific thrombolytic regim

121 ory cytokines have been used with success as adjunctive therapy in genetic disorders such as chronic

122 g regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients.

123 eted against these proteins may be useful as adjunctive therapy in intubated patients with P. aerugin

124 emonstrate treatment shortening by verapamil adjunctive therapy in mice, and strongly support further

125 tion is warranted into the use of statins as adjunctive therapy in mucormycosis.

126 e data suggest that AAT may be beneficial as adjunctive therapy in patients undergoing islet transpla

127 le and effective antithrombotic treatment as adjunctive therapy in patients undergoing percutaneous c

128 ll-tolerated treatment that may be useful as adjunctive therapy in patients with MDR-TB who are other

129 hat clinicians use electrical stimulation as adjunctive therapy in patients with pressure ulcers to a

130 ith or without small-dose cyclosporine (CsA) adjunctive therapy in renal transplant recipients.

131 , there is no evidence for efficacy of ET as adjunctive therapy in severe malaria.

132 able on the use of ENOX compared with UFH as adjunctive therapy in STEMI patients treated with fibrin

133 Gabapentin has come into clinical use as adjunctive therapy in the treatment of epilepsy.

134 xidine (CHX) has been used extensively as an adjunctive therapy in the treatment of periodontal disea

135 a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underway.

136 ses, respectively, and thus may be useful as adjunctive therapy in those intracellular infections in

137 uate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 pa

138 benefit was identified in 21 RCTs evaluating adjunctive therapies including electric current, ultraso

139 treatments are now often prescribed as late adjunctive therapy including pilocarpine, epinephrine co

140 e last decade, clinical trials with numerous adjunctive therapies, including antiendotoxin antibodies

141 ory requirement for separate monotherapy and adjunctive-therapy indications in epilepsy is unnecessar

142 s consistently separated into monotherapy or adjunctive-therapy indications.

143 One proposed adjunctive therapy is sodium valproate (VPA), an anticon

144 primary angioplasty and more frequent use of adjunctive therapies known to reduce mortality, and may

145 logy of progression also suggests that other adjunctive therapies may be possible.

146 Lamotrigine was used as adjunctive therapy (N = 60) or monotherapy (N = 15) in p

147 here is considerable interest in the role of adjunctive therapies, particularly ondansetron and probi

148 e in these patients, but the benefit of this adjunctive therapy remains controversial.

149 and provided new avenues for severe malaria adjunctive therapy research.

150 ltaneous advances in surgical techniques and adjunctive therapies, respiratory care, intensive care t

151 a to guide the clinician in choosing whether adjunctive therapy should be added to optimize response

152 sign features may also include incorporating adjunctive therapies such as antithrombotic or antiproli

153 ombocytopenic purpura, but clinical data for adjunctive therapies, such as corticosteroids, antiplate

154 Promising old and new adjunctive therapies, such as pretreatment with beta-blo

155 S disease, as well as the need for effective adjunctive therapies targeting monocytes and macrophages

156 the rationale to probe potential synergy of adjunctive therapy targeting CD4 and CD154 to overcome g

157 his procedure has been used predominantly as adjunctive therapy, targeting only the patient's clinica

158 rrently treated with antibiotics and various adjunctive therapies that are not very effective.

159 fective antimalarial therapy, development of adjunctive therapies that can attenuate CM progression c

160 Promising adjunctive therapies that target microvascular dysfuncti

161 Such studies hold the promise of a novel adjunctive therapy that could make cancer chemotherapy m

162 ve disorders (HAND) underscores the need for adjunctive therapy that targets the neuropathological pr

163 en HIV and its human host provides hope that adjunctive therapies to antiretroviral treatment can be

164 or and sensory trajectories and a variety of adjunctive therapies to augment the recovery of neurolog

165 tial usefulness of SIB-1508Y and levodopa as adjunctive therapies to improve at least some of the cog

166 percutaneous coronary intervention (PCI), or adjunctive therapies to reperfusion by conducting an ele

167 y weight and glomerular growth may be useful adjunctive therapies to slow or prevent progression to E

168 uency (RF) electric-field hyperthermia as an adjunctive therapy to [60]fullerene nanoparticle-based d

169 s support the role of organic nitrates as an adjunctive therapy to ACE inhibitors in patients with ch

170 Ablation is usually adjunctive therapy to an ICD in these patients.

171 Corticosteroids are a potential adjunctive therapy to antibiotics.

172 Corticosteroids have been avoided as adjunctive therapy to antifungals in the treatment of ac

173 imesylate (LDX), a d-amphetamine prodrug, as adjunctive therapy to antipsychotics in adults with clin

174 ased therapy with interleukin-2 when used as adjunctive therapy to antiretroviral therapy may further

175 h varespladib 500 mg daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on biomar

176 f clinical chemoresistance, and implicate an adjunctive therapy to enhance chemotherapeutic response

177 Nitrite has significant potential as adjunctive therapy to enhance the efficacy of reperfusio

178 ficacy and safety of aerosolized colistin as adjunctive therapy to i.v. antimicrobials or as monother

179 the concept that rapamycin can be used as an adjunctive therapy to improve efficacy of T(reg)-based i

180 SAND, suggesting that it may be an effective adjunctive therapy to increase survival and reduce organ

181 immunomodulators that are being evaluated as adjunctive therapy to interferon-based regimens.

182 The use of pharmacological agents as adjunctive therapy to lifestyle modification is crucial,

183 should consider the use of synbiotics as an adjunctive therapy to prevent POCs among adult surgical

184 ction may represent a specific and effective adjunctive therapy to rapidly reverse the ongoing pathol

185 egulatory T cells (Treg) offer an attractive adjunctive therapy to reduce current reliance on lifelon

186 ging biomarker may be a promising target for adjunctive therapy to reduce the complications associate

187 imicrobial photodynamic therapy (aPDT) as an adjunctive therapy to scaling and root planing (SRP) for

188 proved survival and play a future role as an adjunctive therapy to surgical resection.

189 panders may offer yet another alternative or adjunctive therapy to the early rehabilitation of the co

190 Heparin and hirudin have an equal effect as adjunctive therapy to TPA and streptokinase in preventin

191 s inhibition could potentially be used as an adjunctive therapy to treat microbial keratitis and othe

192 death, and catheter ablation can be used as adjunctive therapy to treat or prevent repetitive ICD th

193 ndividuals, catheter ablation may be used as adjunctive therapy to treat or prevent repetitive ICD th

194 that can be used for testing the efficacy of adjunctive therapy to verteporfin PDT.

195 The potential role of adjunctive therapies used with HFOV (e.g., prone ventila

196 design, including lesion type, location, and adjunctive therapy used.

197 Adjunctive therapy was designed accordingly to deplete p

198 investigation, and empiric antimicrobial and adjunctive therapy were developed.

199 ries has identified potential candidates for adjunctive therapies, which may be combined with surgica

200 Finally, a discussion of adjunctive therapies will be included.

201 Patients were randomly assigned to adjunctive therapy with abciximab or placebo at the begi

202 etter assess clinical outcome are needed for adjunctive therapy with adenosine, K(ATP) channel opener

203 Unlike individual treatment regimens, adjunctive therapy with adenovirus-IL-4 and suboptimal d

204 to L-DOPA, supporting consideration of early adjunctive therapy with an A2A antagonist to reduce the

205 ovide support for clinical trials of MAbs as adjunctive therapy with antiretroviral therapy during ac

206 tial role for antifibrotic drug treatment as adjunctive therapy with ART to improve immune reconstitu

207 Standard adjunctive therapy with aspirin, ticlopidine, and hepari

208 us (Siro) vs. mycophenolate mofetil (MMF) as adjunctive therapy with calcineurin inhibitors (CI) in r

209 that investigate HIV-1-neutralizing MAbs as adjunctive therapy with cART during acute HIV-1 infectio

210 Adjunctive therapy with cyclosporine in this setting doe

211 Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST

212 arin compared with unfractionated heparin as adjunctive therapy with fibrinolysis.

213 The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent fe

214 Adjunctive therapy with granulocyte macrophage colony-st

215 er studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with

216 lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the tre

217 Adjunctive therapy with locally delivered antimicrobials

218 ly protect against drug-resistant strains in adjunctive therapy with meropenem, a standard-of-care an

219 arkers defined a subset of patients in which adjunctive therapy with omalizumab was associated with a

220 dentify subjects most likely to benefit from adjunctive therapy with omalizumab.

221 A double-blind, placebo-controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as

222 her used alone for prevention or possibly as adjunctive therapy with phlebotomy or chelation.

223 y was to evaluate the safety and efficacy of adjunctive therapy with poloxamer 188 in patients receiv

224 Adjunctive therapy with poloxamer 188 resulted in substa

225 Adjunctive therapy with rIFN- gamma 1b holds promise for

226 Adjunctive therapy with second-generation antidepressant

227 nhibitor use as a risk factor and the use of adjunctive therapy with specific probiotic, as it was ap

228 or mycophenolate mofetil (MMF) was tested as adjunctive therapy, with planned dose reductions of tacr

229 ents treated with topical corticosteroids as adjunctive therapy within 2 to 3 days of antibiotic ther